Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.

Climent MÁ, León-Mateos L, González Del Alba A, Pérez-Valderrama B, Méndez-Vidal MJ, Mellado B, Arranz JÁ, Sánchez-Hernández A, Cassinello J, Olmos D, Carles J.

Crit Rev Oncol Hematol. 2015 Nov;96(2):308-18. doi: 10.1016/j.critrevonc.2015.05.019. Review.

PMID:
26100652
2.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology..

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Review.

PMID:
24321502
3.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Review.

PMID:
26196735
4.

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.

Climent MA, Piulats JM, Sánchez-Hernández A, Arranz JÁ, Cassinello J, García-Donas J, González del Alba A, León-Mateos L, Mellado B, Méndez-Vidal MJ, Pérez-Valderrama B; Spanish Oncology Genitourinary Group..

Crit Rev Oncol Hematol. 2012 Sep;83(3):341-52. doi: 10.1016/j.critrevonc.2012.01.002.

PMID:
22285697
5.

[Updated treatments of castration-resistant prostate cancer].

Wei YF, Gu XJ, Zhu QY.

Zhonghua Nan Ke Xue. 2016 May;22(5):455-61. Review. Chinese.

PMID:
27416673
6.

Current management of advanced and castration resistant prostate cancer.

Gomella LG, Petrylak DP, Shayegan B.

Can J Urol. 2014 Apr;21(2 Supp 1):1-6.

7.

Current, new and novel therapy for castration-resistant prostate cancer.

Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.

Expert Rev Anticancer Ther. 2013 Jul;13(7):819-27. doi: 10.1586/14737140.2013.811154. Review.

PMID:
23875660
8.

Advances in systemic therapies for metastatic castration-resistant prostate cancer.

Pant MK, Abughaban A, Aragon-Ching JB.

Future Oncol. 2014 Nov;10(14):2213-26. doi: 10.2217/fon.14.128.

PMID:
25471035
9.

[Management of patients with castration-resistant metastatic prostate cancer].

Ondruš D, Ondrušová M.

Klin Onkol. 2015;28(1):24-9. Review. Czech.

PMID:
25692752
10.

Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.

Ponholzer A, Loidl W, Bektic J, Dorfinger K, Hruby S, Jeschke K, Kramer G, Krause S, Ludvik G, Remzi M, Roider M, Stoiber F.

Wien Klin Wochenschr. 2016 Feb;128(3-4):156-63. doi: 10.1007/s00508-015-0945-x.

PMID:
26831188
11.

Castration-resistant prostate cancer: AUA Guideline.

Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS.

J Urol. 2013 Aug;190(2):429-38. doi: 10.1016/j.juro.2013.05.005.

PMID:
23665272
12.

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.

Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010.

13.

[Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].

Djurhuus SS, Brasso K, Berg KD, Iversen P, Røder MA.

Ugeskr Laeger. 2015 May 11;177(20). pii: V11140628. Review. Danish.

PMID:
25967247
14.

[Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].

Basset V, Flamand V, Crouzet S, Ploussard G.

Prog Urol. 2013 Oct;23 Suppl 1:S44-8. doi: 10.1016/S1166-7087(13)70045-9. Review. French.

PMID:
24314738
15.

[Recomendations on the management of controversies in advanced castrate-resistant prostate cancer].

Cózar JM, Solsona E, Morote J, Miñana B, Maroto JP, González Del Alba A, Climent MA, Carles J, Alcaraz A, Castellano D; Asociación Española de Urología.; Grupo de Urología Oncológica.; Grupo Español de Oncología Genitourinaria..

Actas Urol Esp. 2012 Nov-Dec;36(10):569-77. doi: 10.1016/j.acuro.2012.06.004. Spanish.

PMID:
22999347
16.

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Ryan CJ, Saylor PJ, Everly JJ, Sartor O.

Oncologist. 2014 Oct;19(10):1012-8. doi: 10.1634/theoncologist.2013-0472. Review.

17.

New developments in the treatment of castration resistant prostate cancer.

Wadia R, Petrylak DP.

Asian J Androl. 2014 Jul-Aug;16(4):555-60. doi: 10.4103/1008-682X.127824. Review.

18.

The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Geethakumari PR, Cookson MS, Kelly WK; Prostate Cancer Clinical Trials Working Group 3..

Oncology (Williston Park). 2016 Feb;30(2):187-95, 199. Review.

19.

Current state of castration-resistant prostate cancer.

Petrylak DP.

Am J Manag Care. 2013 Dec;19(18 Suppl):s358-65. Review.

20.

A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer.

Ryan C, Shore ND, Concepcion R.

Postgrad Med. 2013 Nov;125(6):114-6. doi: 10.3810/pgm.2013.11.2718.

PMID:
24200767
Items per page

Supplemental Content

Support Center